{"id":"amifostine-trihydrate","safety":{"commonSideEffects":[{"rate":"50-90%","effect":"Nausea and vomiting"},{"rate":"15-62%","effect":"Hypotension"},{"rate":"12-25%","effect":"Hypocalcemia"},{"rate":"1-2%","effect":"Allergic reactions"},{"rate":"10-15%","effect":"Somnolence"},{"rate":"5-10%","effect":"Hiccups"}]},"_chembl":{"chemblId":"CHEMBL1006","moleculeType":"Small molecule","molecularWeight":"214.23"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amifostine is dephosphorylated by alkaline phosphatase to form WR-1065, the active metabolite, which preferentially accumulates in normal tissues due to higher alkaline phosphatase activity. The active thiol metabolite neutralizes reactive oxygen species and electrophilic compounds, protecting normal cells from chemotherapy and radiation-induced damage while having limited protective effect on tumor cells due to their lower alkaline phosphatase activity.","oneSentence":"Amifostine is a prodrug that is converted to an active free thiol compound, which acts as a cytoprotective and radioprotective agent by scavenging free radicals and reducing DNA damage.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:42:13.191Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Reduction of cumulative renal toxicity associated with repeated cisplatin administration in patients with advanced ovarian cancer"},{"name":"Reduction of xerostomia (dry mouth) in patients undergoing postoperative radiation treatment for head and neck cancer"}]},"trialDetails":[{"nctId":"NCT00003927","phase":"PHASE1","title":"Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"1999-05-18","conditions":"Breast Cancer","enrollment":15},{"nctId":"NCT00052884","phase":"PHASE1","title":"Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation","status":"TERMINATED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2004-01-22","conditions":"Drug/Agent Toxicity by Tissue/Organ, Multiple Myeloma and Plasma Cell Neoplasm","enrollment":8},{"nctId":"NCT05785663","phase":"","title":"AminoMedixTM for Kidney Protection During Radionuclide Therapy","status":"COMPLETED","sponsor":"Excel Diagnostics and Nuclear Oncology Center","startDate":"2014-08-08","conditions":"Radiation Nephropathy","enrollment":28},{"nctId":"NCT00003407","phase":"PHASE2","title":"Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML","status":"WITHDRAWN","sponsor":"Rush University Medical Center","startDate":"2001-02-13","conditions":"Drug/Agent Toxicity by Tissue/Organ, Leukemia, Myelodysplastic Syndromes","enrollment":""},{"nctId":"NCT00274937","phase":"PHASE3","title":"Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2006-02-20","conditions":"Stage I Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7, Stage I Nasopharyngeal Undifferentiated Carcinoma AJCC v7, Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7","enrollment":111},{"nctId":"NCT00003777","phase":"PHASE2","title":"Surgery, Radiation Therapy, and Combination Chemotherapy in Treating Patients With Recurrent Head and Neck Cancer","status":"TERMINATED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"1998-12","conditions":"Head and Neck Cancer","enrollment":35},{"nctId":"NCT00003405","phase":"PHASE2","title":"Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia","status":"WITHDRAWN","sponsor":"Rush University Medical Center","startDate":"1998-04","conditions":"Leukemia","enrollment":""},{"nctId":"NCT00003225","phase":"PHASE1, PHASE2","title":"Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"1997-07","conditions":"Colorectal Cancer","enrollment":23},{"nctId":"NCT00003048","phase":"PHASE2","title":"Amifostine in Treating Patients With Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"1997-06-05","conditions":"Myelodysplastic Syndromes","enrollment":12},{"nctId":"NCT00003926","phase":"PHASE1","title":"Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"1998-11","conditions":"Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Chordoma","enrollment":13},{"nctId":"NCT00503776","phase":"PHASE2","title":"Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia","status":"TERMINATED","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2006-01","conditions":"Dysphagia, Head and Neck Cancer, Mucositis","enrollment":41},{"nctId":"NCT00003582","phase":"PHASE1, PHASE2","title":"Radiation Therapy, Combination Chemotherapy, and Amifostine in Treating Patients With Head and Neck Cancer","status":"COMPLETED","sponsor":"University of Miami","startDate":"1988-05","conditions":"Carcinoma of Unknown Primary, Head and Neck Cancer","enrollment":36},{"nctId":"NCT00006012","phase":"PHASE1, PHASE2","title":"Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2001-02","conditions":"Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Radiation Toxicity","enrollment":73},{"nctId":"NCT00217438","phase":"PHASE3","title":"Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2005-07","conditions":"Refractory Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma","enrollment":130},{"nctId":"NCT00012012","phase":"PHASE1, PHASE2","title":"Radiation Therapy and Cisplatin With or Without Amifostine for Patients With Stage IIIB or IVA Cervical Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2001-08","conditions":"Cervical Cancer, Radiation Toxicity","enrollment":45},{"nctId":"NCT00003313","phase":"PHASE3","title":"Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"1998-09","conditions":"Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Oral Complications","enrollment":243},{"nctId":"NCT00098683","phase":"PHASE2","title":"Amifostine in Treating Young Patients With Newly Diagnosed De Novo Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2005-01","conditions":"Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms","enrollment":10},{"nctId":"NCT00004036","phase":"PHASE1","title":"Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer","status":"UNKNOWN","sponsor":"The Cleveland Clinic","startDate":"1997-11","conditions":"Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ, Leukemia","enrollment":30},{"nctId":"NCT00003827","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome","status":"UNKNOWN","sponsor":"ALZA","startDate":"1999-01","conditions":"Leukemia, Myelodysplastic Syndromes","enrollment":25},{"nctId":"NCT00003583","phase":"PHASE2","title":"Amifostine to Prevent Side Effects in Patients Who Are Receiving Chemotherapy and Radiation Therapy for Limited-Stage Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"University of Florida","startDate":"1997-06","conditions":"Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Radiation Toxicity","enrollment":20},{"nctId":"NCT00003251","phase":"PHASE1, PHASE2","title":"Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer","status":"UNKNOWN","sponsor":"University of Illinois at Chicago","startDate":"1997-12","conditions":"Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer, Radiation Toxicity","enrollment":46},{"nctId":"NCT00004264","phase":"PHASE1, PHASE2","title":"Docetaxel, Cisplatin, and Amifostine in Treating Patients With Advanced Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"University of Wisconsin, Madison","startDate":"1997-07","conditions":"Drug/Agent Toxicity by Tissue/Organ, Lung Cancer","enrollment":""},{"nctId":"NCT00003123","phase":"PHASE2","title":"Amifostine in Treating Patients With Advanced Myelodysplastic Syndrome","status":"UNKNOWN","sponsor":"Providence Hospital","startDate":"1997-08","conditions":"Myelodysplastic Syndromes","enrollment":36},{"nctId":"NCT00006105","phase":"PHASE2","title":"Gemcitabine, Cisplatin, and Amifostine Following Surgery in Treating Patients With Locally Advanced Bladder Cancer","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2000-06","conditions":"Bladder Cancer, Drug/Agent Toxicity by Tissue/Organ","enrollment":37},{"nctId":"NCT00003268","phase":"PHASE1","title":"Amifostine and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"1998-01","conditions":"Drug/Agent Toxicity by Tissue/Organ, Leukemia","enrollment":""},{"nctId":"NCT00003089","phase":"PHASE2","title":"Chemotherapy, Amifostine, and Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"1997-07","conditions":"Drug/Agent Toxicity by Tissue/Organ, Lung Cancer","enrollment":""},{"nctId":"NCT00058071","phase":"PHASE3","title":"Amifostine in Treating Peripheral Neuropathy in Patients Who Have Received Chemotherapy for Cancer","status":"COMPLETED","sponsor":"Gynecologic Oncology Group","startDate":"2003-03","conditions":"Gestational Trophoblastic Tumor, Neurotoxicity, Peripheral Neuropathy","enrollment":100},{"nctId":"NCT00003811","phase":"PHASE2","title":"Combination Chemotherapy Plus Amifostine in Treating Children With Malignant Germ Cell Tumors","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2000-04","conditions":"Childhood Germ Cell Tumor, Drug/Agent Toxicity by Tissue/Organ, Extragonadal Germ Cell Tumor","enrollment":27},{"nctId":"NCT00004919","phase":"PHASE1","title":"Irinotecan and Cisplatin With or Without Amifostine in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1999-12","conditions":"Unspecified Childhood Solid Tumor, Protocol Specific","enrollment":30},{"nctId":"NCT00003555","phase":"PHASE1","title":"Paclitaxel Plus Chemoprotection With Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors","status":"COMPLETED","sponsor":"State University of New York - Upstate Medical University","startDate":"1998-07","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":20},{"nctId":"NCT00003580","phase":"PHASE2","title":"Amifostine to Treat Side Effects of Treatment in Patients Receiving Radiation Therapy and Cisplatin for Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"University of Tennessee","startDate":"1998-06","conditions":"Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer, Oral Complications","enrollment":""},{"nctId":"NCT00003994","phase":"PHASE3","title":"Combination Chemotherapy With or Without Amifostine in Treating Young Patients With Liver Cancer","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"1999-03","conditions":"Childhood Hepatoblastoma, Recurrent Childhood Liver Cancer, Stage I Childhood Liver Cancer","enrollment":277},{"nctId":"NCT00004176","phase":"PHASE2","title":"Amifostine, Chemotherapy, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"1998-10","conditions":"Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Radiation Toxicity","enrollment":34},{"nctId":"NCT00003425","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect","status":"COMPLETED","sponsor":"University of Kentucky","startDate":"1997-12","conditions":"Breast Cancer, Leukemia, Lymphoma","enrollment":25},{"nctId":"NCT00003624","phase":"PHASE2","title":"Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer","status":"TERMINATED","sponsor":"Gynecologic Oncology Group","startDate":"1998-12","conditions":"Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer","enrollment":""},{"nctId":"NCT00003252","phase":"PHASE4","title":"Amifostine in Treating Patients With Cancer Who Have Neurological Changes Caused by Chemotherapy","status":"COMPLETED","sponsor":"Rush North Shore Medical Center","startDate":"1997-12","conditions":"Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":""},{"nctId":"NCT00003136","phase":"PHASE1, PHASE2","title":"Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"University of Chicago","startDate":"1996-12","conditions":"Ovarian Cancer, Primary Peritoneal Cavity Cancer","enrollment":11},{"nctId":"NCT00002643","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1995-04","conditions":"Neutropenia, Sarcoma","enrollment":130},{"nctId":"NCT00003068","phase":"PHASE2","title":"High-Dose Chemotherapy and Autologous Blood Cell Transplantation in Treating Patients With Primary, Locally Advanced, or Stage IV Breast Cancer","status":"COMPLETED","sponsor":"University of Arizona","startDate":"1997-06","conditions":"Breast Cancer, Drug/Agent Toxicity by Tissue/Organ","enrollment":30},{"nctId":"NCT00003415","phase":"PHASE1, PHASE2","title":"Amifostine Plus Topotecan in Treating Patients With Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"University of Arizona","startDate":"1998-09","conditions":"Leukemia, Myelodysplastic Syndromes","enrollment":26},{"nctId":"NCT00005598","phase":"PHASE2","title":"Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2000-10","conditions":"Myelodysplastic Syndromes","enrollment":""},{"nctId":"NCT00003193","phase":"PHASE1, PHASE2","title":"Paclitaxel and Radiation Therapy Plus Chemoprotection With Amifostine in Treating Patients With Stage III or Stage IV Head and Neck Cancer","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"1998-01","conditions":"Head and Neck Cancer, Oral Complications","enrollment":37},{"nctId":"NCT00003211","phase":"PHASE2","title":"Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"1996-10","conditions":"Brain and Central Nervous System Tumors","enrollment":94},{"nctId":"NCT00078845","phase":"PHASE2","title":"Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2004-05","conditions":"Breast Cancer, Lung Cancer, Neurotoxicity","enrollment":24},{"nctId":"NCT00025298","phase":"PHASE2","title":"Chemotherapy Plus Radiation Therapy With or Without Amifostine in Treating Patients With Locally Advanced Cancer of the Nasopharynx","status":"TERMINATED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2001-07","conditions":"Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer, Oral Complications","enrollment":5},{"nctId":"NCT00003072","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With Metastatic Ovarian Cancer or Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"1997-05","conditions":"Lung Cancer, Neurotoxicity, Ovarian Cancer","enrollment":80},{"nctId":"NCT00003127","phase":"PHASE2","title":"S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"1998-02","conditions":"Endometrial Cancer","enrollment":57},{"nctId":"NCT00004166","phase":"PHASE3","title":"Amifostine in Treating Patients With Ovarian Epithelial Cancer Who Are Receiving Chemotherapy","status":"COMPLETED","sponsor":"Northwestern University","startDate":"1999-10","conditions":"Ovarian Cancer, Quality of Life","enrollment":""},{"nctId":"NCT00040365","phase":"PHASE2","title":"Amifostine to Protect the Rectum During External Beam Radiotherapy for Prostate Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-06","conditions":"Prostatic Neoplasms","enrollment":30},{"nctId":"NCT00003144","phase":"PHASE1","title":"Chemotherapy and Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"1997-08","conditions":"Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":44},{"nctId":"NCT00003294","phase":"PHASE1","title":"Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"1997-05","conditions":"Leukemia, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":24},{"nctId":"NCT00003269","phase":"PHASE2","title":"Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors","status":"COMPLETED","sponsor":"Scripps Health","startDate":"1998-02","conditions":"Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer","enrollment":20},{"nctId":"NCT00003307","phase":"PHASE2","title":"Radiation Therapy Plus Amifostine in Treating Patients With Primary Prostate Cancer","status":"COMPLETED","sponsor":"University of Arizona","startDate":"1998-03","conditions":"Prostate Cancer, Radiation Toxicity","enrollment":25},{"nctId":"NCT00003681","phase":"PHASE2","title":"Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome","status":"UNKNOWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1998-08","conditions":"Anemia, Myelodysplastic Syndromes","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ethyol","ethyol","ethanethiol","ethiofos","gammaphos"],"phase":"marketed","status":"active","brandName":"amifostine trihydrate","genericName":"amifostine trihydrate","companyName":"City of Hope Medical Center","companyId":"city-of-hope-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Amifostine is a prodrug that is converted to an active free thiol compound, which acts as a cytoprotective and radioprotective agent by scavenging free radicals and reducing DNA damage. Used for Reduction of cumulative renal toxicity associated with repeated cisplatin administration in patients with advanced ovarian cancer, Reduction of xerostomia (dry mouth) in patients undergoing postoperative radiation treatment for head and neck cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}